for only. Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021 Catalyst Pharmaceuticals’s last day, last week, and last month’s high and low average amplitude percentage was 7.36%, 5.65%, and 4.63%, respectively. Sector Healthcare RiskRating. Welcome to the Catalyst Pharmaceuticals Facebook page! What Is The Ownership Structure Like For Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)? Headline. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value . Free trial. Looking Into Catalyst Pharmaceuticals's Return On Capital Employed. Monthly Subscription. That’s why we believe that, when you’re battling a rare disease—it’s all about the company you keep. Yahoo. Free trial. Get the latest Catalyst Pharmaceuticals Inc (CPRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Catalyst Pharmaceuticals on Wikipedia, Google News & Yahoo Finance. The "next" GameStop is certain to be hit fast and hard. We joined the Facebook community so you can connect with Catalyst and we can provide you with Catalyst news updates, activities, and other events and resources that might be of interest. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), and spinal muscular atrophy (SMA) Type 3. View the latest Catalyst Pharmaceuticals Inc. (CPRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is 30.84% higher on its value in year-to-date trading and has touched a low of $2.60 and a high of $5.19 in the current 52-week trading range. Here’s what analysts think will happen to its price in the coming time. Catalyst Pharmaceuticals’s stock is valued at $4.23 at 16:45 EST, way under its 52-week high of $5.28 and way higher than its 52-week low of $2.55. Penny Stocks to Buy Using Technical Analysis for February 2021. $80.29. Plus, the 36-month beta value for CPRX is at 1.38. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) scored a price-to-earnings ratio above its average ratio, recording 6.71 x from its present earnings ratio. Get Catalyst Pharmaceuticals Inc (CPRX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced an expansion in its strategic priorities related to portfolio planning and research and development. Time (ET) Yahoo. CPRX | Complete Catalyst Pharmaceuticals Inc. stock news by MarketWatch. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Catalyst Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Catalyst Pharmaceuticals's CPRX shares and potentially its market environment have … Small Cap Basic. View real-time stock prices and stock quotes for a full financial overview. Catalyst Pharmaceuticals Sees Higher … Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value. 02/13 02:41. 01/29 15:07. I quite like to see at least a little bit of insider ownership. Free trial. Return. Catalyst Pharmaceuticals had a net margin of 60.48% and a return on equity of 35.04%. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Catalyst Pharmaceuticals News. Investor Contact Solebury Trout (646) 378-2923: Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse® : Catalyst Pharmaceutical Press Releases : Catalyst Pharmaceutical Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal : Catalyst Pharmaceutical. Catalyst Pharmaceuticals (NASDAQ CPRX) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance MT Newswires. The content on this Facebook page is intended for U.S. audiences and any health topics that may be discussed do not constitute medical advice. Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is 10.18% higher on its value in year-to-date trading and has touched a low of $2.55 and a high of $5.19 in the current 52-week trading range. Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity. Ultimate Trader (Monthly) Monthly Subscription. In a year-end update , the company announced the completion of the first pharmacokinetic study testing three of Firdapse’s most promising candidate formulations. We joined the Facebook community so you can connect with Catalyst and we can provide you with Catalyst news updates, activities, and other events and resources that might be of interest. Stock Advisor Flagship service. Latest Stock Picks Investing Basics Premium Services. CPRX - Catalyst Pharmaceuticals Inc Share News. Big Cap Pro. Perhaps the WallStreetBets message board on Reddit will target Catalyst Pharmaceuticals or TherapeuticsMD stock. Often patients feel isolated and hopeless. Wire. Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. The content on this Facebook page is intended for U.S. audiences and any health topics that may be discussed do not constitute medical advice. Here’s what analysts think will happen to its price in the coming time. Catalyst Pharmaceuticals’s last day, last week, and last month’s high and low average amplitude percentage was 7.73%, 4.95%, and 4.46%, respectively. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Description : Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy … Development of a new long-acting formulation of Firdapse (amifampridine) remains on track, according to Catalyst Pharmaceuticals, the therapy’s developer. for only. Adventurous. 01/28 10:44 . The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. for only. Monthly Subscription. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Catapults 28% Though Its Price And Business Still Lag The Market. Follow CPRX. Catalyst Pharmaceuticals News . Catalyst Pharmaceuticals Inc () Stock Market info Recommendations: Buy or sell Catalyst Pharmaceuticals stock? Best deals to access real time data! $52.04. Now, Catalyst Pharmaceuticals stock found itself facing two forces, both of them negative. Furthermore, Catalyst Pharmaceuticals, Inc. (CPRX)’s beta value is 1.38, and its average true range (ATR) is 0.25. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.02, Fidelity Earnings reports. At Catalyst, our three core values are: Passion, Trust, and Integrity with a strong focus on patients as our first priority. At Catalyst Pharmaceuticals, we understand that receiving a rare disease diagnosis can be extremely difficult. S&P. Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020 2nd Nov '20 News BRIEF-Catalyst Pharmaceuticals Announces Filing Of Patent Infringement Actions Against Jacobus Pharmaceuticals And Pantherrx $4.31 0.0 0.7% Last Trade - 18/02/21. Catalyst Pharmaceuticals (NASDAQ:CPRX) posted its earnings results on Monday. Real time Catalyst Pharmaceuticals (CPRX) stock price quote, stock graph, news & analysis. Every investor in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should be aware of the most powerful shareholder groups. $33.03. Our commitment to the LEMS and Neuromuscular community goes beyond FDA approval of our investigational medicine(s). VAT not included. Welcome to the Catalyst Pharmaceuticals Facebook page! Yahoo. A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. The company’s stock has been forecasted to trade at an average price of $7.5 over the course of the next 52 weeks, with a low of $5.5 and a high of $9.